The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe
Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT prescription guidelines and monitoring vary across countries. Standardising the approach to diagnosis of disease course, for ex...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-09-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/17562864231198963 |
| _version_ | 1797673256511078400 |
|---|---|
| author | Richard Nicholas Jeff Rodgers James Witts Annalaura Lerede Tim Friede Jan Hillert Lars Forsberg Anna Glaser Ali Manouchehrinia Ryan Ramanujam Tim Spelman Pernilla Klyve Jiri Drahota Dana Horakova Hanna Joensen Luigi Pontieri Melinda Magyari David Ellenberger Alexander Stahmann Helmut Butzkueven Anneke Van Der Walt Vladimir Bezlyak Carol Lines Rod Middleton |
| author_facet | Richard Nicholas Jeff Rodgers James Witts Annalaura Lerede Tim Friede Jan Hillert Lars Forsberg Anna Glaser Ali Manouchehrinia Ryan Ramanujam Tim Spelman Pernilla Klyve Jiri Drahota Dana Horakova Hanna Joensen Luigi Pontieri Melinda Magyari David Ellenberger Alexander Stahmann Helmut Butzkueven Anneke Van Der Walt Vladimir Bezlyak Carol Lines Rod Middleton |
| author_sort | Richard Nicholas |
| collection | DOAJ |
| description | Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT prescription guidelines and monitoring vary across countries. Standardising the approach to diagnosis of disease course, for example, assigning RRMS or secondary progressive MS (SPMS) diagnoses, allows examination of the impact of health system characteristics on the stated clinical diagnosis and treatment access. Methods: We analysed registry data from six cohorts in five countries (Czech Republic, Denmark, Germany, Sweden and United Kingdom) on patients with an initial diagnosis of RRMS. We standardised our approach utilising a pre-existing algorithm (DecisionTree, DT) to determine patient diagnoses of RRMS or secondary progressive MS (SPMS). We identified five global drivers of DMT prescribing: Provision, Availability, Funding, Monitoring and Audit, data were analysed against these concepts using meta-analysis and univariate meta-regression. Results: In 64,235 patients, we found variations in DMT use between countries, with higher usage in RRMS and lower usage in SPMS, with correspondingly lower usage in the UK compared to other registers. Factors such as female gender ( p = 0.041), increasing disability via Expanded Disability Status Scale (EDSS) score ( p = 0.004), and the presence of monitoring ( p = 0.029) in SPMS influenced the likelihood of receiving DMTs. Standardising the diagnosis revealed differences in reclassification rates from clinical RRMS to DT-SPMS, with Sweden having the lowest rate Sweden (Sweden 0.009, range: Denmark 0.103 – UK portal 0.311). Those with higher EDSS at index ( p < 0.03) and female gender ( p < 0.049) were more likely to be reclassified from RRMS to DT-SPMS. The study also explored the impact of diagnosis on DMT usage in clinical SPMS, finding that the prescribing environment and auditing practices affected access to treatment. Discussion: This highlights the importance of a healthcare system’s approach to verifying the clinical label of MS course in facilitating appropriate prescribing, with some flexibility allowed in uncertain cases to ensure continued access to treatment. |
| first_indexed | 2024-03-11T21:41:53Z |
| format | Article |
| id | doaj.art-94019eea78bf46cdb31bf422481b6086 |
| institution | Directory Open Access Journal |
| issn | 1756-2864 |
| language | English |
| last_indexed | 2024-03-11T21:41:53Z |
| publishDate | 2023-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Neurological Disorders |
| spelling | doaj.art-94019eea78bf46cdb31bf422481b60862023-09-26T13:03:28ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28642023-09-011610.1177/17562864231198963The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across EuropeRichard NicholasJeff RodgersJames WittsAnnalaura LeredeTim FriedeJan HillertLars ForsbergAnna GlaserAli ManouchehriniaRyan RamanujamTim SpelmanPernilla KlyveJiri DrahotaDana HorakovaHanna JoensenLuigi PontieriMelinda MagyariDavid EllenbergerAlexander StahmannHelmut ButzkuevenAnneke Van Der WaltVladimir BezlyakCarol LinesRod MiddletonIntroduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT prescription guidelines and monitoring vary across countries. Standardising the approach to diagnosis of disease course, for example, assigning RRMS or secondary progressive MS (SPMS) diagnoses, allows examination of the impact of health system characteristics on the stated clinical diagnosis and treatment access. Methods: We analysed registry data from six cohorts in five countries (Czech Republic, Denmark, Germany, Sweden and United Kingdom) on patients with an initial diagnosis of RRMS. We standardised our approach utilising a pre-existing algorithm (DecisionTree, DT) to determine patient diagnoses of RRMS or secondary progressive MS (SPMS). We identified five global drivers of DMT prescribing: Provision, Availability, Funding, Monitoring and Audit, data were analysed against these concepts using meta-analysis and univariate meta-regression. Results: In 64,235 patients, we found variations in DMT use between countries, with higher usage in RRMS and lower usage in SPMS, with correspondingly lower usage in the UK compared to other registers. Factors such as female gender ( p = 0.041), increasing disability via Expanded Disability Status Scale (EDSS) score ( p = 0.004), and the presence of monitoring ( p = 0.029) in SPMS influenced the likelihood of receiving DMTs. Standardising the diagnosis revealed differences in reclassification rates from clinical RRMS to DT-SPMS, with Sweden having the lowest rate Sweden (Sweden 0.009, range: Denmark 0.103 – UK portal 0.311). Those with higher EDSS at index ( p < 0.03) and female gender ( p < 0.049) were more likely to be reclassified from RRMS to DT-SPMS. The study also explored the impact of diagnosis on DMT usage in clinical SPMS, finding that the prescribing environment and auditing practices affected access to treatment. Discussion: This highlights the importance of a healthcare system’s approach to verifying the clinical label of MS course in facilitating appropriate prescribing, with some flexibility allowed in uncertain cases to ensure continued access to treatment.https://doi.org/10.1177/17562864231198963 |
| spellingShingle | Richard Nicholas Jeff Rodgers James Witts Annalaura Lerede Tim Friede Jan Hillert Lars Forsberg Anna Glaser Ali Manouchehrinia Ryan Ramanujam Tim Spelman Pernilla Klyve Jiri Drahota Dana Horakova Hanna Joensen Luigi Pontieri Melinda Magyari David Ellenberger Alexander Stahmann Helmut Butzkueven Anneke Van Der Walt Vladimir Bezlyak Carol Lines Rod Middleton The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe Therapeutic Advances in Neurological Disorders |
| title | The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe |
| title_full | The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe |
| title_fullStr | The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe |
| title_full_unstemmed | The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe |
| title_short | The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe |
| title_sort | impact of healthcare systems on the clinical diagnosis and disease modifying treatment usage in relapse onset multiple sclerosis a real world perspective in five registries across europe |
| url | https://doi.org/10.1177/17562864231198963 |
| work_keys_str_mv | AT richardnicholas theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT jeffrodgers theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT jameswitts theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT annalauralerede theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT timfriede theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT janhillert theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT larsforsberg theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT annaglaser theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT alimanouchehrinia theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT ryanramanujam theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT timspelman theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT pernillaklyve theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT jiridrahota theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT danahorakova theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT hannajoensen theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT luigipontieri theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT melindamagyari theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT davidellenberger theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT alexanderstahmann theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT helmutbutzkueven theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT annekevanderwalt theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT vladimirbezlyak theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT carollines theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT rodmiddleton theimpactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT richardnicholas impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT jeffrodgers impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT jameswitts impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT annalauralerede impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT timfriede impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT janhillert impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT larsforsberg impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT annaglaser impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT alimanouchehrinia impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT ryanramanujam impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT timspelman impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT pernillaklyve impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT jiridrahota impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT danahorakova impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT hannajoensen impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT luigipontieri impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT melindamagyari impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT davidellenberger impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT alexanderstahmann impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT helmutbutzkueven impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT annekevanderwalt impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT vladimirbezlyak impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT carollines impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope AT rodmiddleton impactofhealthcaresystemsontheclinicaldiagnosisanddiseasemodifyingtreatmentusageinrelapseonsetmultiplesclerosisarealworldperspectiveinfiveregistriesacrosseurope |